| References |
Top |
| REF 1 |
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell. 2012 Aug 31;150(5):987-1001.
|
| REF 2 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 3 |
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011 Nov 15;20(5):620-34.
|
| REF 4 |
Physical interaction of mammalian CDC37 with CDK4. J Biol Chem. 1996 Sep 6;271(36):22030-4.
|
| REF 5 |
Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997 Sep 1;16(17):5334-44.
|
| REF 6 |
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994 Dec 15;8(24):2939-52.
|
| REF 7 |
A novel partner for D-type cyclins: protein kinase A-anchoring protein AKAP95. Biochem J. 2004 Mar 1;378(Pt 2):673-9.
|
| REF 8 |
p21(Cip1) up-regulated during histone deacetylase inhibitor-induced CD4(+) T-cell anergy selectively associates with mitogen-activated protein kinases. Immunology. 2010 Apr;129(4):589-99.
|
| REF 9 |
PCAF acts as a gastric cancer suppressor through a novel PCAF-p16-CDK4 axis. Am J Cancer Res. 2016 Dec 1;6(12):2772-2786.
|
| REF 10 |
Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004 Jul 8;430(6996):226-31.
|
